West Pharmaceutical Services, Inc. (WST) — BATS 0/100 — 2026-07-23

Listen to the earnings call audio for free on StockAnalysis

Summary based on West Pharmaceutical Services, Inc. earnings call on 2026-07-23

BotFlo AI Transformation Score for $WST: 0 (0/100)

Sector AI Transformation Score for $WST: 0 (0/50)

Presentation

(1/6) Strong Q2 results and raised full-year guidance
• 📈 Q2 revenues of $872 million rose 13% organically and adjusted EPS of $2.37 rose 29% versus prior year, exceeding expectations.
• 🚀 Management raised full-year 2026 organic revenue growth guidance to 10% to 11% and adjusted EPS to $8.85 to $9.05.
• 🛡️ Results were attributed to strategy execution, operational excellence, and colleague efforts recovering from a cyber incident.

(2/6) HVP components led by biologics, Annex 1 upgrades, and GLP-1
• 💉 Proprietary Products grew 16% organically, with Biologics up 29% and HVP components up 18% organically to 49% of company revenues.
• 🧬 Three growth drivers were biologics and biosimilars, HVP upgrades including Annex 1, and continued strength in GLP-1 elastomers.
• 📊 Non-GLP-1 HVP components rose high teens organically and were the largest contributor to quarterly outperformance, while Annex 1 mix shift is targeted to deliver 200 basis points of revenue growth in 2026.

(3/6) Delivery devices, Standard Products, West Vantage, and Daikyo renewal
• 📦 HVP delivery devices rose 29% organically, aided by stronger SmartDose 3.5 orders ahead of the July 1 sale of manufacturing and supply rights.
• 🔄 Standard Products were up slightly and remain a funnel for HVP upgrades that improve revenue and margins without incremental volume.
• 🤝 West Vantage grew 1% organically, slightly below expectations due to the cyber incident, and existing strategic agreements with Daikyo were renewed.

(4/6) Detailed P&L, cash flow, and capital allocation
• 💰 Gross margin was 37.7%, up 200 basis points year-over-year, and adjusted operating margin was 22.6%, up 230 basis points, driven by HVP mix and price.
• 🏦 Operating cash flow was $124 million and capex $43 million, with full-year capex still expected at $250 million to $275 million.
• 📉 West continued its $1 billion share repurchase program, buying just over 0.5 million shares for $157 million in Q2 and 1.8 million shares for $454 million in the first half.

(5/6) Updated full-year and Q3 financial guidance
• 📈 Full-year revenue is now expected at $3.345 billion to $3.38 billion, or 10% to 11% organic growth, with adjusted EPS of $8.85 to $9.05.
• 🎯 Total HVP components are now expected to grow high teens organically for the year for both GLP-1 and non-GLP-1, with over 200 basis points of operating margin expansion versus 2025.
• 📅 Q3 revenue is guided to $820 million to $835 million organically up 7% to 8.9%, with adjusted EPS of $2.14 to $2.24, and West Vantage expected to trough in Q3 as the CGM contract exits.

(6/6) Strategy affirmation and CEO leadership transition
• 🧭 Management said financial strength reaffirms the growth strategy and a durable competitive moat focused on biologics, GLP-1s, and Annex 1 HVP conversions.
• 👋 Eric Green will pass leadership to Michel Lagarde on August 31 and expressed pride in the organization and gratitude to the Board and One West team.
• ✅ West remains focused on capitalizing on long-term macro trends while leveraging global scale for customers and shareholders.

Q&A

(1/16) Q&A: Drivers and sustainability of non-GLP-1 HVP component strength
• 🧬 Non-GLP-1 HVP strength is driven by greater than 90% participation in new biologic molecules, uptake of existing molecules, and biosimilar expansion.
• 🧪 Annex 1 and HVP upgrades now total just shy of 800 projects, up 50% year-over-year, enabling higher ASP and margin mix with no incremental volume via washing and Envision.
• 🌍 Management called these long-term macro trends with early-innings conversion on roughly 6 billion EU units and emerging U.S. spillover, supported by operational excellence after the cyber incident.

(2/16) Q&A: Conservatism in second-half guide after another strong quarter
• 📉 The analyst asked whether the second-half guide still looks conservative after the Q2 beat and raise, given Vantage cyber timing and SmartDose.
• 🧭 Bob said the company is taking a prudent one-quarter-at-a-time approach and investors should not read too much into the guide shape.
• 💪 Underlying momentum in HVP components is expected to drive a strong second half and full year on both top line and profit.

(3/16) Q&A: Capacity utilization at Eschweiler, Grand Rapids, and Dublin
• 🏭 Eschweiler, the largest HVP components plant, saw double-digit productivity and throughput gains in the first half that enabled cyber recovery.
• ⚙️ The same methodology is being expanded across HVP sites, with capital still deployed within a 6% to 8% of sales framework when needed.
• 📍 Grand Rapids is near expected 2026 throughput levels, while Dublin drug handling remains in ramp with revenues more back-end loaded into Q4 and 2027.

(4/16) Q&A: Second-half margin bridge, pricing, and mix trajectory
• 💵 Price accelerated to 4 points of growth in Q2, above the 2% to 3% corridor, as part of a multiyear value-capture journey.
• 📊 HVP components drive attractive incremental margins; Q3 margin performance is expected roughly flat versus Q2 with about 200 basis points full-year expansion and potential upside.
• 🔧 Multi-year opportunities remain across footprint, gross margin, OpEx productivity, and below-the-line performance.

(5/16) Q&A: GLP-1 trends, generics, and oral versus injectable dynamics
• 💉 GLP-1 demand is playing out as anticipated with large players, and West continues to support multiple modalities in the marketplace.
• 🌏 Generic and biosimilar GLP-1s, especially from China and Korea, were a key driver of strong Asia growth and represent additional geographic and patient-population opportunity.
• 🔬 New late-stage indications and the view that orals expand rather than cannibalize injectables support long-term confidence in West’s GLP-1 position.

(6/16) Q&A: Delivery devices pipeline after SmartDose 3.5 divestiture
• 📱 After closing SmartDose 3.5 on July 1, self-dose with multiple customers and molecules is a key self-injection growth driver with healthy expansion.
• 🧪 Crystal Zenith targets high-end biologics including cell and gene therapy and remains a clear leverage opportunity.
• 📈 Self-injection and Crystal Zenith are double-digit growth portfolios while administration systems grow mid- to high-single digits, with a more attractive margin profile excluding SmartDose 3.5.

(7/16) Q&A: Stack-ranking HVP portfolio drivers of mix shift
• 🥇 Biologics are the strongest HVP growth driver, using the highest-end NovaPure and FluroTec products with the highest ASPs and margins.
• 🥈 Annex 1 upgrades often start from core or standard formulations and add pharma washing and Envision without reopening stability testing, making them margin-accretive though lower on the spectrum.
• 🔄 Customers are also upgrading within HVP, adding further value steps beyond standard-to-HVP conversion, supporting multiyear Annex 1 staying power.

(8/16) Q&A: Whether Annex 1 contribution can accelerate beyond 200 bps
• ❓ The analyst asked if growing projects, geographic spillover, and within-HVP upgrades imply an accelerating Annex 1 trajectory versus a steady 200 basis points.
• 📌 Bob said 200 basis points is well placed today but there is possibility and opportunity to accelerate.
• ⏳ Investors were told to stay tuned regarding potential further acceleration.

(9/16) Q&A: APAC growth drivers and West Vantage drug-handling margins
• 🌏 Asia Pacific’s 27% organic growth was led by China, then India and South Korea, with generic or biosimilar GLP-1s as the largest current engine and strong India approval participation.
• 🏭 Increasing CDMO work, including in South Korea, positions West to support multinationals’ primary packaging configurations in the region.
• 📦 Drug handling is on track for about $20 million of revenue, mostly back-half loaded with a real step-up in Q4; Q3 is likely the Vantage revenue trough while margins improve quarter-on-quarter into 2027.

(10/16) Q&A: GLP-1 second-half guide shape and OUS generics timing
• 📉 The apparent steep second-half GLP-1 slowdown in the guide reflects prudence rather than anything seen in the marketplace.
• 📰 Constructive GLP-1 news, U.S. expansion, and next-generation products support expectations for continued market expansion and adoption.
• 🌐 OUS generic opportunities are helping this year but are characterized as larger contributors in 2027 and beyond outside the U.S. and Europe.

(11/16) Q&A: Proprietary margins and SmartDose dilutive impact post-divestiture
• 💎 HVP components remain the most margin-accretive part of the business.
• 📤 SmartDose 3.5 was dilutive in the first half and its second-half exit is still expected to contribute 50 basis points of incremental margin for the full year, or about 100 basis points in H2.
• 📈 Margin progression is expected to continue improving through the back half and into 2027 and beyond.

(12/16) Q&A: Medicare GLP-1 expansion impact on ordering and guidance
• 🏥 Medicare-related changes should expand the market and increase volume, which is a net benefit for West.
• 🤝 Customer discussions and forecasting already factor the opportunity so West can supply product in a timely manner.
• ⏳ Volume expansion is expected to ramp over time rather than appear all at once.

(13/16) Q&A: Delivery devices growth cadence excluding SmartDose pull-forward
• 📊 The analyst noted the devices guide improved from mid-singles at the start of the year and that core growth remains solid even excluding SmartDose ordering.
• ✅ Bob agreed the rest of the portfolio has enjoyed really nice growth reflecting underlying dynamics Eric described earlier.
• 📅 Expectations are that this core delivery-devices momentum will continue into Q3 and Q4.

(14/16) Q&A: Through-cycle growth algorithm and proprietary ex-GLP guide
• 🔁 On through-cycle growth, Bob said momentum remains constructive and West expects to participate disproportionately versus market growth, with further work alongside incoming leadership.
• 💉 GLP-1 HVP is guided to high teens for the full year, expected to be consistent in the second half.
• 📈 Proprietary overall is low double digits, non-GLP-1 HVP is also high teens, standard products are flattish to slightly better, and delivery devices continue to perform well.

(15/16) Q&A: Reconciling reported GLP-1 elastomer growth math versus high teens
• 🔢 The analyst calculated roughly 40% year-on-year GLP-1 growth from percent-of-revenue disclosures versus management’s high-teens characterization.
• 📌 Bob reiterated growth was high teens, noted roughly 10% of revenue in Q1 as well, and suggested possible West Vantage or modeling differences.
• ✅ Eric and Bob emphasized confidence in continued GLP-1 portfolio performance despite rounding or mix bridging questions.

(16/16) Q&A: Pricing outlook amid energy and commodity cost inflation
• ⛽ Management has been evaluating higher oil and commodity costs and passing some of those costs through to customers as done in the past.
• 💵 Price has ticked up over recent quarters as West seeks to better capture platform value.
• 📅 In the second half, cost pass-through is expected to be a bigger piece of price given marketplace dynamics.